Supplemental material
Leukemia & Lymphoma
Volume 64, 2023 - Issue 3
Letters to the Editor
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study
David Quallsa Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
https://orcid.org/0000-0001-5297-9685View further author information
https://orcid.org/0000-0001-5297-9685View further author information, Ariela Noyb Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;c Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USAhttps://orcid.org/0000-0002-3001-4898View further author information
https://orcid.org/0000-0002-3001-4898View further author information, David Strausb Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;c Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USAhttps://orcid.org/0000-0001-8364-6816View further author information
https://orcid.org/0000-0001-8364-6816View further author information, Matthew Matasarb Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;c Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USAhttps://orcid.org/0000-0002-4581-3721View further author information
https://orcid.org/0000-0002-4581-3721View further author information, Craig Moskowitzb Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;d Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USAhttps://orcid.org/0000-0002-9189-3152View further author information
https://orcid.org/0000-0002-9189-3152View further author information, , Ahmet Doganf Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USAhttps://orcid.org/0000-0001-6576-5256View further author information
https://orcid.org/0000-0001-6576-5256View further author information, Gilles Sallesb Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;c Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USAhttps://orcid.org/0000-0002-9541-8666View further author information
https://orcid.org/0000-0002-9541-8666View further author information, Anas Younesb Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAhttps://orcid.org/0000-0002-0001-4133View further author information
https://orcid.org/0000-0002-0001-4133View further author information, Andrew D. Zelenetzb Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;c Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USAhttps://orcid.org/0000-0003-1403-6883View further author information
https://orcid.org/0000-0003-1403-6883View further author information & Connie Lee Batlevib Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;c Weill Cornell Department of Medicine, Weill Cornell Medical College, New York, NY, USACorrespondence[email protected]
https://orcid.org/0000-0002-9036-9463View further author information
https://orcid.org/0000-0002-9036-9463View further author information show all